Project Grant R01CA288403
Award Date 5/1/24
Completion Date 4/30/29
Dollars Obligated $2.9M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) is providing $827,942.00 to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to investigate a novel inhibitory receptor that regulates the persistence and function of chimeric antigen receptor (CAR)-engineered T cell therapy for lymphoma. The key objectives are to: 1) examine the causal role of this inhibitory receptor axis in impairing the therapeutic...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $399,958 to Mabswitch Inc., a minority-owned small business, to assess the feasibility of regulating the activation, effector functions, and cytokine release of chimeric antigen receptor (CAR) T-cell therapies. The project aims to develop a "switchable affinity CAR" (SAEFCAR) that can be controlled by an exogenously administered ligand, potentially mitigating the toxicity...
- This $400,000 Project Grant was awarded on August 4, 2025 by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The grant supports research conducted by Lifengine Animal Health Laboratories Incorporated to develop chimeric antigen receptor (CAR)-T cell therapies that can overcome functional exhaustion. Specifically, the project aims to engineer CAR-T cells to overexpress the C-MYB transcription factor, which has been shown in mice to enhance anti-tumor...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to Kure Ai Inc. to develop a novel CAR-T cell therapy product targeting the MR1 antigen expressed on the surface of various tumor cells, including acute myeloid leukemia (AML) and glioblastoma. The key objectives are to: 1) assess MR1 expression in primary patient AML and glioblastoma samples, 2) perform mouse efficacy studies using AML and glioblastoma models, and 3)...
- This $399,669 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to establish the feasibility of commercializing a personalized and multi-targeted adoptive T cell therapy (ATCT) for glioblastoma (GBM), the most common and deadly primary brain tumor. The key products or services to be delivered under this grant include: Evaluating the ability of the applicant's Prussian blue nanoparticle-based photothermal therapy (PBNP-PTT) platform to...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) is focused on enhancing cancer therapeutics through the development of a 3-in-1 Chimeric Antigen Receptor (CAR) T cell approach. The $398,997 award, effective July 1, 2025 through June 30, 2026, supports research by Immunogenik, Inc. to target tumor-associated myeloid cells (TAMCs), including tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs), which play a...
- This federal Project Grant award of $470,759 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research to develop a novel CAR T-cell therapy for patients with hepatocellular carcinoma. The goal is to prevent CAR T-cell exhaustion, a key barrier to effective solid tumor treatment, by overexpressing the JMJD6 transcription factor using a precise, RNA-level control system called the "PA-Regulator" platform. The research, conducted...
- This $1,340,987 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to revolutionize chimeric antigen receptor (CAR) T-cell therapy by developing a novel "CAR-Enhancer" platform to improve the effector function and persistence of CAR T-cells. The project's key objectives are to: 1) Optimize dosing and timing for CAR-Enhancer administration in a Phase I clinical trial, 2) Establish a scalable manufacturing process, and 3) Assess the...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) is supporting a Phase 2 multi-center clinical trial of a novel CD5 CAR T-cell therapy (MB-105) developed by March Biosciences Inc. for the treatment of relapsed/refractory T-cell lymphoma (R/R TCL). The $1,124,607 award, with a performance period of Jul 1, 2025 to Jun 30, 2027, aims to validate the safety and efficacy of this innovative cellular therapy that is engineered to selectively target...
- The National Cancer Institute (NCI) awarded a $402,600 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the Sloan-Kettering Institute for Cancer Research to develop novel chimeric antigen receptor (CAR) T-cell therapies targeting the U5 small nuclear ribonucleoprotein (U5 snRNP) complex for the treatment of acute myeloid leukemia (AML). The primary goals of this 5-year project are to develop these CAR T-cell therapies and investigate the mechanism by which U5 snRNP is...